<

INVENTIVA (EPA:IVA) Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

Transparency directive : regulatory news

07/03/2024 22:00



Other stories

29/04/2024 08:56
29/04/2024 04:28
29/04/2024 06:38
29/04/2024 05:47
29/04/2024 07:00
28/04/2024 19:32
29/04/2024 00:47
29/04/2024 06:00
28/04/2024 22:33
28/04/2024 19:41
29/04/2024 09:32
28/04/2024 13:46
29/04/2024 04:17
28/04/2024 16:26
29/04/2024 06:14
28/04/2024 15:58
29/04/2024 07:09
29/04/2024 07:04
29/04/2024 00:32
29/04/2024 06:00
29/04/2024 05:00
28/04/2024 14:59
29/04/2024 07:00
28/04/2024 20:02
29/04/2024 09:33
29/04/2024 07:00
29/04/2024 08:18
29/04/2024 08:00
29/04/2024 08:00
28/04/2024 23:41
29/04/2024 08:08
27/04/2024 20:48
28/04/2024 09:42
27/04/2024 21:03
28/04/2024 12:18
28/04/2024 08:51
27/04/2024 13:26
29/04/2024 00:00